Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT)